Explore by health topic
View allGLP-1
Semaglutide, tirzepatide, retatrutide, side effects, dosing, and access.
Peptides
Recovery, metabolism, skin health, and evidence-based peptide guides.
Drug Guides
Plain-language coverage of major GLP-1 medications and comparisons.
Diet & Side Effects
Food, protein, fiber, nausea, fatigue, reflux, and long-term routines.
Latest
New guides from Middleway
GLP-1
CagriSema vs Retatrutide: Which Wins on Weight Loss?
CagriSema (cagrilintide + semaglutide) delivered up to 22.7% weight loss in REDEFINE 1, while retatrutide reached 28.3% in its first pivotal phase 3 trial. Here is how the two next-generation obesity drugs compare on data, mechanism, dosing, and timeline.
GLP-1
Orforglipron vs Retatrutide: Oral Pill vs Injectable Triple Agonist
Orforglipron is an FDA-approved once-daily oral GLP-1 pill that delivered about 12.4% weight loss in phase 3. Retatrutide is an investigational weekly injectable triple agonist that reached roughly 24% in phase 2. This guide compares convenience, efficacy, mechanism, and who each suits.
GLP-1
Mazdutide vs Retatrutide: Dual vs Triple Agonist
Mazdutide is a GLP-1/glucagon dual agonist approved in China, while retatrutide is an investigational GIP/GLP-1/glucagon triple agonist. We compare mechanisms, trial weight loss, and market status.
GLP-1
UBT251 vs Retatrutide: Triple Agonist Comparison
UBT251 and retatrutide are both GLP-1/GIP/glucagon triple agonists, but they sit at very different stages. Retatrutide has full phase 3 data; UBT251 has early phase 1 and Chinese phase 2 results. Here is how they compare on mechanism, trials, and timeline.
GLP-1
Retatrutide Cycle: Length, Titration, and What to Expect
A retatrutide cycle is the full arc of treatment: slow titration over about three months, a steady maintenance phase, and a planned exit. Here is what the phase 2 and phase 3 trial schedules actually used, and why stopping tends to bring weight back.
GLP-1
Retatrutide vs Mounjaro: Triple Agonist vs Tirzepatide
Mounjaro (tirzepatide) is an FDA-approved dual GLP-1/GIP agonist for type 2 diabetes. Retatrutide is an investigational triple agonist that added glucagon and hit higher weight-loss numbers in trials, but it is not yet approved.
GLP-1
Trulicity Coupon (2026): Savings Card Terms and Every Way to Pay Less
Lilly's Trulicity savings card takes the copay to as little as $25 — capped at $150/month and $1,950/year, commercial insurance only. Cash payers face ~$987-$1,113 retail with no generic in sight until after 2027. Every legitimate discount, with current 2026 terms.
GLP-1
Wegovy Generic: Is There One in 2026? What Exists Instead
There is no FDA-approved generic Wegovy in 2026. It's the same molecule as Ozempic — semaglutide — wearing a weight-loss label. The practical 'generic price' today is the $149 oral pill or the $349 NovoCare cash route, not a true generic.
GLP-1
How to Get Ozempic (2026): Qualification, Prescription, Telehealth
Ozempic is FDA-approved for type 2 diabetes, not weight loss — so who prescribes it, and for whom, depends entirely on your diagnosis. Here is the qualification reality, the telehealth routes, the insurance gauntlet, and the $349-$499 cash path.